Biotech Values

[ghmm]

CTMX:

In going through the JP Morgan webcasts I found this company interesting. I don't do much pure Oncology investing and so I'm not as comfortable here so I thought to ask if anyone is familiar with the company. More so what people think of their technology/approach of developing what they call "probodies". They are basically antibodies designed to bind later and avoid some of the toxicity. I am not sure if this leads to increased/decreased or no improvement on efficacy. Since it seems Immunotherapy is heading to 2-3 agents I thought their approach was interesting. Their market cap, spend, partnership and potential for more made them interesting to me. They are early but since people were posting on PD-1/PD-L1 thought to mention them since they have programs in both.

Here is a paper on their approach for anyone interested:
http://stm.sciencemag.org/content/5/207/207ra144?sid=53d5596f-0be2-44ff-b735-86e3e54983bd

The company website is here:
http://cytomx.com/

And this is their JPM slide presentation:
http://phx.corporate-ir.net/External.File?t=1&item=VHlwZT0yfFBhcmVudElEPTUyNDYxMjN8Q2hpbGRJRD02NTY4MzA=